Avalon Pharma profit jumps 50% to SAR 52.5M in 9M 2025; Q3 at SAR 8.3M

05/11/2025 Argaam Exclusive

Content Summary:

Loading data...

Comments Analysis:

Positive: 0%
Neutral: 0%
Negative: 0%
Comments Summary:Loading data...
Please note that this news summary has been generated using artificial intelligence. It is recommended to review the original sources for complete details and to verify the accuracy of the information.

Middle East Pharmaceutical Industries Co. (Avalon Pharma) posted a net profit of SAR 52.5 million in the first nine months of 2025, a leap of 50% from SAR 35 million in the year-earlier period.

 


Financials (M)

Item 9m 2024 9m 2025 Change‬
Revenues 258.01 322.97 25.2 %
Gross Income 154.28 196.37 27.3 %
Operating Income 43.79 61.58 40.6 %
Net Income 35.04 52.49 49.8 %
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items (Riyals) 1.75 2.62 49.8 %
EPS (Riyal) 1.75 2.62 49.8 %

The profit rise was attributed to a 25% year-on-year (YoY) increase in revenue to SAR 322.97 million in 9M 2025. This growth was driven by higher sales in the private sector (+26%), government sector (+34%), and export sector (+7%).

 

Stronger sales in key therapeutic areas also supported overall revenue growth.

 

The gross profit margin improved across all distribution channels.

 

However, selling, distribution, general and administrative expenses increased, reflecting the company’s ongoing investment in sustainable long-term growth.

 

The company's Q3 2025 net profit surged 114.1% to SAR 8.28 million, compared to SAR 3.87 million a year earlier.

 

Sequentially, net earnings plunged 66.6% from SAR 24.81 million in Q2 2025.



Current Quarter Comparison (M)

Compared With The
Item Q3 2024 Q3 2025 Change‬
Revenues 81.06 107.95 33.2 %
Gross Income 45.70 62.47 36.7 %
Operating Income 6.94 11.01 58.6 %
Net Income 3.87 8.28 114.1 %
Average Shares 20.00 20.00 -
Earnings Per Share before unusual items (Riyal) 0.19 0.41 114.1 %
EPS (Riyal) 0.19 0.41 114.1 %

Shareholders' equity, with no minority interest, rose to SAR 371.33 million as of Sept. 30, 2025, compared to SAR 326.19 million in the prior-year period.

Attached document:

 

 

View More Financial Results

 

View other reports

Share Price

Middle East Pharmaceutical Industries Co.
127.70
(2.30) (1.77 %)

Middle East Pharmaceutical Industries Co. (AVALON PHARMA)

More


Financial Ratios
Current
Market Cap (M Riyal) 2,560.00
Enterprise Value (EV) (M Riyal) 2,602.98
Shares Outstanding ((M)) 20.00
EPS ( Riyal) (TTM) 4.86
Book Value (BV) ( Riyal) 18.57
Par Value ( Riyal) 10.00
Recurring P/E 26.31
P/E (TTM) 26.31
Price/book 6.89
Return on Average Assets (%) (TTM) 18.4
Return on Average Equity (%) (TTM) 27.9
EV/adj EBITDA -
EV/Revenues 5.67
more

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2025, Argaam Investment, All Rights Reserved
Call Request